R60 – Single Vial
$45.00
In Stock. Ready to Ship.
Retatrutide (R60) is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors — making it one of the most researched peptides in the metabolic science space right now.
Our R60 single vials have been independently tested and verified:
- Fill: 69.84 mg
- Purity: 99.539%
- Testing: Janoshik Included
For research purposes only.
Out of stock|In stock and ready to ship
Description
What Is Retatrutide?
Retatrutide is a synthetic 39-amino acid peptide designed to activate three distinct metabolic receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).
It was developed by Eli Lilly and Company under the research designation LY3437943, and is informally referred to as a “triple G” agonist within the research community.
What makes Reta stand out from earlier compounds in this class is the third receptor target. GLP-1 receptor agonists like semaglutide and liraglutide address only a subset of the biological pathways governing energy balance. Dual agonists like tirzepatide added GIP receptor activation. Retatrutide extends this further by incorporating glucagon receptor activation — adding thermogenic, lipolytic, and hepatic fat-oxidizing mechanisms not accessible through single or dual agonists.
How It’s Been Studied
Retatrutide has been studied in a Phase 2 trial involving adults without diabetes but with obesity or pre-obesity, and is currently being evaluated in Phase 3 clinical trials.
Phase 2 results demonstrated significant weight reduction in overweight and obese adults, with reported average losses of 17.5% and 24.4% at 24 and 48 weeks, respectively.
Phase 3 trials under the TRIUMPH program began enrolling in 2023 across populations with obesity combined with cardiovascular disease, type 2 diabetes, metabolic liver disease, chronic kidney disease, obstructive sleep apnea, and knee osteoarthritis.
Why the Structure Matters
Retatrutide’s backbone derives from GIP, modified at three positions with non-natural amino acids. Alpha-aminoisobutyric acid (Aib) substitutions at positions 2 and 20 increase resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and other proteases. Retatrutide has a relatively long half-life of approximately 6 days, which supports once-weekly administration and contributes to sustained effectiveness.
Our R60 Test Results
We don’t just tell you it’s quality — we show you.
- Fill: 69.84 mg
- Purity: 99.539%
- Testing: Janoshik — certificate included
This is the standard you should expect. If a vendor can’t show you the test, that’s your answer.
Disclaimer: This product is intended for research purposes only. It is not approved for human use. All research must be conducted in accordance with applicable laws and regulations.
